Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation

The Lancet

Volumn 345, Issue 8950, 1995, Pages 610-614

  Hollander, A A M J ^a   van Saase, J L C M ^a,b   van Es, L A ^a   van derWoude, F J ^a   van Bockel, H J ^a   Kootte, A M M ^c   van Dorp, W T ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b St Clara Hospital   (Netherlands)

^c RIJNLAND HOSPITAL   (Netherlands)

^d Department of Internal Medicine Rijnland Hospital ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYPERTENSIVE AGENT; PREDNISONE;

ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DRUG SAFETY; GRAFT SURVIVAL; HEART DEATH; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0028966518     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)90520-0     Document Type: Article

References (20)

1. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy
2. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial
3. A randomized clinical trial of cyclosporine in cadaveric renal transplantation
4. Cyclosporin A in patients receiving renal allografts from cadaver donors
5. Chronic irreversible nephrotoxicity from cyclosporin A
6. Controlled cyclosporine conversion at three months after renal transplantation
7. High- and low-dose regimens of cyclosporine in renal transplantation: immunosuppressive efficacy and side effects
8. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long term cyclosporine, short term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine
9. Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients
10. Elective cyclosporine withdrawal after renal transplantation: a meta-analysis
11. Improved patient and graft survival after treatment of acute rejections of cadaveric renal allografts with rabbit antithymocyte globulin
12. Conversion from cyclosporine to azathioprine in renal allograft recipients
13. Improvement of renal function after conversion from cyclosporine only to prednisolone-azathioprine followed by late-onset graft failure in renal transplant patients
14. Management of cyclosporine nephrotoxicity by conversion to azathioprine or by reduction of cyclosporine dose and addition of azathioprine
15. Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation
16. The adverse impact of cyclosporine on serum lipids in renal transplant recipients
17. Systemic hypertension associated with cyclosporin: a review
18. Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: results of the Minnesota randomized trial comparing cyclosporine versus antilymphocyte globulin-azathioprine
19. Collaborative transplant study—10 year report
20. Cyclosporine-induced hyperuricemia and gout